Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder

ClinicalTrials.gov ID: NCT00321490

Public ClinicalTrials.gov record NCT00321490. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled and Active-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD

Study identification

NCT ID
NCT00321490
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

  • Duloxetine Drug
  • Quetiapine fumarate Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2006
Primary completion
Not listed
Completion
Apr 30, 2007
Last update posted
Mar 24, 2009

2006 – 2007

United States locations

U.S. sites
34
U.S. states
25
U.S. cities
34
Facility City State ZIP Site status
Research Site Birmingham Alabama
Research Site Scottsdale Arizona
Research Site Beverly Hills California
Research Site San Diego California
Research Site Sherman Oaks California
Research Site Wildomar California
Research Site Boca Raton Florida
Research Site Bradenton Florida
Research Site Jacksonville Florida
Research Site Orlando Florida
Research Site Tampa Florida
Research Site West Palm Beach Florida
Research Site Edwardsville Illinois
Research Site Lake Charles Louisiana
Research Site Baltimore Maryland
Research Site Haverhill Massachusetts
Research Site Okemos Michigan
Research Site Saint Paul Minnesota
Research Site St Louis Missouri
Research Site Princeton New Jersey
Research Site Albuquerque New Mexico
Research Site New York New York
Research Site Dayton Ohio
Research Site Mayfield Village Ohio
Research Site Oklahoma City Oklahoma
Research Site Salem Oregon
Research Site Philadelphia Pennsylvania
Research Site Columbia South Carolina
Research Site Memphis Tennessee
Research Site Houston Texas
Research Site Salt Lake City Utah
Research Site Richmond Virginia
Research Site Kirkland Washington
Research Site Morgantown West Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00321490, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 24, 2009 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00321490 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →